Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb announces expansion of Erbitux agreement

Bristol-Myers Squibb announces expansion of Erbitux agreement

1st August 2007

Bristol-Myers Squibb has announced a change to its previous agreement with ImClone Systems regarding the development and promotion of Erbitux (cetuximab).

Under the terms of the revised agreement, the firms have agreed to increase the investment in the continuing clinical development programme for the compound by several hundred million dollars.

Bristol Myers-Squibb is responsible for all development costs up to a set limit, after which further costs will be shared by both firms.

These funds will be used in a number of phase II and phase III clinical studies to assess the activity of Erbitux in a number of oncology settings, with the anticipation of further opportunities to register the compound with regulatory authorities.

Elliott Sigal, executive vice-president, chief scientific officer and president of research and development at Bristol-Myers Squibb, said: “We intend to enhance cancer patient outcomes which may further differentiate Erbitux from other commercially available antibodies.”

He added that the extension of this development agreement shows the commitment of Bristol-Myers Squibb to forming collaborations that can fully exploit the potential of compounds in its drug portfolio.

Earlier this month, Bristol-Myers Squibb announced the results of a phase III clinical trial exploring the use of Erbitux as a combination therapy with carboplatin and taxane as a first-line treatment for patients with metastatic non-small cell lung cancer.

The firm reported that the compound showed positive results for key secondary endpoints, though the primary endpoint of independently-measured progression-free survival was not met.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.